HAART non-HAART
Sample size 12 13
% Males 83.3 84.6
Age (years) 46 ± 8 52 ± 11         
Black African (%) 100 84.6                     
Body mass index (kg/m2) 23.0 ± 5.0 24.5 ± 3.1
% Obese 8.3 7.7
% Hypertensive 8.3 23.1
% With diabetes mellitus 8.3 7.7
Current smoker (%) 75.0 69.0
Regular alcohol (%) 75.0 61.5
Systolic blood pressure (mm Hg) 130 ± 20 129 ± 21
Diastolic blood pressure (mm Hg) 82 ± 10 76 ± 13
Glycated hemoglobin (%) 5.95 ± 0.30 5.98 ± 0.97
Total/HDL cholesterol 3.35 ± 1.00 4.15 ± 1.30
LDL cholesterol (mmol/l) 2.10 ± 0.73 2.53 ± 0.83
HDL cholesterol (mmol/l) 1.36 ± 0.53 1.06 ± 0.27          
Triglycerides (mmol/l) 1.47 ± 0.73 1.46 ± 0.85
CD4 count (x106/l) 334 ± 95 316 ± 149
Carotid IMT (mm) 0.74 ± 0.10 0.76 ± 0.14
Duration of treatment (years) 1.2 ± 0.9 (range 0.3 to 1.5) -
HIV- Human Immundeficiency Virus; IMT- Intima-Media Thickness.
Table 2: Characteristics of treated (HAART) versus non-treated (non-HAART) HIV+ patients with critical limb ischemia.